A first-in-human, single and multiple dose study of lunsekimig
Lunsekimig is a novel, bispecific NANOBODY® molecule that inhibits both thymic stromal lymphopoietin (TSLP) and interleukin (IL)-13, two key mediators of asthma pathophysiology. In …
Lunsekimig(Lunsekimig) - 药物靶点：IL-13 x TSLP_在研适应症： …
Lunsekimig is a novel, bispecific NANOBODY® molecule that inhibits both thymic stromal lymphopoietin (TSLP) and interleukin (IL)‐13, two key mediators of asthma pathophysiology.
双靶机制，协同增效！Lunsekimig带来哮喘治疗新突破
2024年12月10日 · Lunsekimig是哮喘治疗领域首个双重阻断TSLP与IL-13的纳米抗体，具有独特的结构优势： 纳米抗体 [5-8] ： 体积小，仅有传统单克隆抗体的十分之一；高稳定性，耐PH值 …
A first‐in‐human, single and multiple dose study of lunsekimig, a …
Lunsekimig is a novel, bispecific NANOBODY® molecule that inhibits both thymic stromal lymphopoietin (TSLP) and interleukin (IL)‐13, two key mediators of asthma pathophysiology. In …
A proof-of-mechanism trial in asthma with lunsekimig, a
This study assessed the safety and tolerability of lunsekimig, a bispecific NANOBODY® molecule that blocks thymic stromal lymphopoietin and interleukin-13, and its effect on Type 2 …
国内首款！赛诺菲「TNFR1抑制剂」在华获批临床 - yaozh.com
Lunsekimig（SAR443765）由赛诺菲开发，是一款将靶向IL-13和靶向TSLP的重链可变区（VHH）连接在一起的纳米抗体，其中TSLP是目前唯一被证明对低Th2型哮喘有效的靶点。 …
Lunsekimig is a novel, bispecific NANOBODY® molecule that inhibits both thymic stromal lymphopoietin (TSLP) and interleukin (IL)- 13, two key media-tors of asthma pathophysiology.
lunsekimig（一种新型抗 TSLP/抗 IL-13 NANOBODY® 化合物）在 …
Lunsekimig 是一种新型双特异性 NANOBODY® 分子，可抑制胸腺基质淋巴细胞生成素 (TSLP) 和白细胞介素 (IL)-13，这是哮喘病理生理学的两个关键介质。 在这项首次人体研究中，我们评 …
lunsekimig using single-cell RNAseq analysis •Explore markers that correlate with pharmacodynamic response (eg, FeNO) Hypothesis: Lunsekimig modulates signaling …
赛诺菲新药lunsekimig注射液在华再次获批临床试验 拟用于治疗哮喘
2024年11月13日 · Lunsekimig是一款胸腺基质淋巴细胞生成素(TSLP)和白细胞介素-13(IL-13)双重阻断剂。 IL-13和TSLP都是在免疫学和炎症领域已经经过验证的靶点，也是哮喘病理生理的关 …